{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1021.11","meta":{"versionId":"13","lastUpdated":"2016-03-31T01:00:12.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"TJC EH Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2016-03-31"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.11","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1021.11"}],"version":"20160331","name":"InjectableFactorXaInhibitorForVTEProphylaxisIngredientSpecific","title":"Injectable factor Xa inhibitor for VTE prophylaxis ingredient specific","status":"active","experimental":false,"date":"2016-03-31T01:00:12-04:00","publisher":"TJC EH Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: Injectable factor Xa inhibitors for VTE prophylaxis as independent ingredients for use in noting the most general idea of this type of therapy. Initial use is for representation of a medication \"not done\". The desire is to have a single choice.),(Data Element Scope: Medication order or discharge NOT DONE),(Inclusion Criteria: Only single ingredient, ingredient-level representation of Injectable factor Xa inhibitors for VTE prophylaxis.),(Exclusion Criteria: None.)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","concept":[{"code":"321208","display":"fondaparinux"}]}]},"expansion":{"identifier":"urn:uuid:78c63339-4d07-4b1c-bd24-a86bf802fd6b","timestamp":"2023-12-10T20:25:46-05:00","total":1,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"321208","display":"fondaparinux"}]}}